EA029470B1 - Способ стимулирования формирования защитного иммунитета против норовируса - Google Patents
Способ стимулирования формирования защитного иммунитета против норовируса Download PDFInfo
- Publication number
- EA029470B1 EA029470B1 EA201490258A EA201490258A EA029470B1 EA 029470 B1 EA029470 B1 EA 029470B1 EA 201490258 A EA201490258 A EA 201490258A EA 201490258 A EA201490258 A EA 201490258A EA 029470 B1 EA029470 B1 EA 029470B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- norovirus
- genogroup
- vaccine
- dose
- ubr
- Prior art date
Links
- 241001263478 Norovirus Species 0.000 title claims abstract description 308
- 238000000034 method Methods 0.000 title claims abstract description 45
- 230000001681 protective effect Effects 0.000 title claims abstract description 32
- 230000036039 immunity Effects 0.000 title claims abstract description 19
- 229960005486 vaccine Drugs 0.000 claims abstract description 245
- 108090000565 Capsid Proteins Proteins 0.000 claims abstract description 53
- 102100023321 Ceruloplasmin Human genes 0.000 claims abstract description 52
- 230000003612 virological effect Effects 0.000 claims abstract description 19
- 239000002245 particle Substances 0.000 claims abstract description 18
- 241000700605 Viruses Species 0.000 claims description 76
- 239000002671 adjuvant Substances 0.000 claims description 44
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 24
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 23
- 238000007918 intramuscular administration Methods 0.000 claims description 23
- 230000015572 biosynthetic process Effects 0.000 claims description 22
- 241000532184 Norovirus GII Species 0.000 claims description 20
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 15
- 239000000872 buffer Substances 0.000 claims description 14
- 241000532183 Norovirus GI Species 0.000 claims description 13
- 108091035707 Consensus sequence Proteins 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 10
- 230000004936 stimulating effect Effects 0.000 claims description 9
- 239000000556 agonist Substances 0.000 claims description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- 239000007983 Tris buffer Substances 0.000 claims description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 3
- 239000000203 mixture Substances 0.000 abstract description 40
- 241000282414 Homo sapiens Species 0.000 abstract description 20
- 239000000427 antigen Substances 0.000 description 76
- 102100040294 Protein unc-50 homolog Human genes 0.000 description 75
- 108091007433 antigens Proteins 0.000 description 66
- 102000036639 antigens Human genes 0.000 description 66
- 210000002966 serum Anatomy 0.000 description 62
- 108090000623 proteins and genes Proteins 0.000 description 52
- 230000004044 response Effects 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 41
- 230000028993 immune response Effects 0.000 description 41
- 229940068196 placebo Drugs 0.000 description 36
- 239000000902 placebo Substances 0.000 description 36
- 102000004169 proteins and genes Human genes 0.000 description 32
- 230000003053 immunization Effects 0.000 description 29
- 238000002649 immunization Methods 0.000 description 29
- 241000282412 Homo Species 0.000 description 28
- 208000024891 symptom Diseases 0.000 description 28
- 230000000903 blocking effect Effects 0.000 description 25
- 238000004458 analytical method Methods 0.000 description 22
- 208000015181 infectious disease Diseases 0.000 description 22
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 21
- 229940024545 aluminum hydroxide Drugs 0.000 description 20
- 150000001720 carbohydrates Chemical class 0.000 description 20
- 235000014633 carbohydrates Nutrition 0.000 description 20
- 230000035931 haemagglutination Effects 0.000 description 20
- 230000001404 mediated effect Effects 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- 230000000405 serological effect Effects 0.000 description 17
- 230000003248 secreting effect Effects 0.000 description 16
- 235000002639 sodium chloride Nutrition 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 208000006339 Caliciviridae Infections Diseases 0.000 description 14
- 238000003556 assay Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 229940031416 bivalent vaccine Drugs 0.000 description 12
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 210000003719 b-lymphocyte Anatomy 0.000 description 11
- 210000003743 erythrocyte Anatomy 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 238000007911 parenteral administration Methods 0.000 description 11
- ZIZJYYVBPLIXGF-KDLZIFBQSA-N (3s)-3-amino-4-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethy Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 ZIZJYYVBPLIXGF-KDLZIFBQSA-N 0.000 description 10
- 108010079682 cholecystokinin 10 C-terminal fragment Proteins 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 9
- 230000005847 immunogenicity Effects 0.000 description 9
- 230000002458 infectious effect Effects 0.000 description 9
- 210000000234 capsid Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241001617329 Norovirus isolates Species 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 101000932768 Conus catus Alpha-conotoxin CIC Proteins 0.000 description 6
- 210000004400 mucous membrane Anatomy 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 229960002885 histidine Drugs 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000012678 infectious agent Substances 0.000 description 5
- 230000015788 innate immune response Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 210000001806 memory b lymphocyte Anatomy 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 231100000279 safety data Toxicity 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 4
- 208000000112 Myalgia Diseases 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 230000028996 humoral immune response Effects 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000701447 unidentified baculovirus Species 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000005577 Gastroenteritis Diseases 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
- 102100031269 Putative peripheral benzodiazepine receptor-related protein Human genes 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 230000010530 Virus Neutralization Effects 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 229940037003 alum Drugs 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000010211 hemagglutination inhibition (HI) assay Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical class [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 2
- 206010024769 Local reaction Diseases 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- -1 UR1 proteins Chemical class 0.000 description 2
- 102100029096 Urotensin-2B Human genes 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 208000012873 acute gastroenteritis Diseases 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000013011 aqueous formulation Substances 0.000 description 2
- HPYIIXJJVYSMCV-MGDXKYBTSA-N astressin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]1C(N[C@@H](C)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@@H](CCCCNC(=O)CC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)=O)C(C)C)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CNC=N1 HPYIIXJJVYSMCV-MGDXKYBTSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 235000019878 cocoa butter replacer Nutrition 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002095 exotoxin Substances 0.000 description 2
- 231100000776 exotoxin Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000006054 immunological memory Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940031346 monovalent vaccine Drugs 0.000 description 2
- 230000016379 mucosal immune response Effects 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920002627 poly(phosphazenes) Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000001650 pulsed electrochemical detection Methods 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101710170564 Bradykinin-potentiating peptide Proteins 0.000 description 1
- 101100441244 Caenorhabditis elegans csp-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241001660259 Cereus <cactus> Species 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101100438439 Escherichia coli (strain K12) ygbT gene Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 206010061166 Gastroenteritis bacterial Diseases 0.000 description 1
- 101001109685 Homo sapiens Nuclear receptor subfamily 5 group A member 2 Proteins 0.000 description 1
- 101000747867 Homo sapiens Upstream-binding protein 1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101100500493 Mus musculus Eapp gene Proteins 0.000 description 1
- 101100346927 Mus musculus Muc19 gene Proteins 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 102100022669 Nuclear receptor subfamily 5 group A member 2 Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 241000350481 Pterogyne nitens Species 0.000 description 1
- 101150003561 RBR gene Proteins 0.000 description 1
- 229940124859 Rotavirus vaccine Drugs 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100026140 TCF3 fusion partner Human genes 0.000 description 1
- 102100033489 THO complex subunit 1 Human genes 0.000 description 1
- 101710139423 THO complex subunit 1 Proteins 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 101100329497 Thermoproteus tenax (strain ATCC 35583 / DSM 2078 / JCM 9277 / NBRC 100435 / Kra 1) cas2 gene Proteins 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 102100040065 Upstream-binding protein 1 Human genes 0.000 description 1
- 102400001279 Urodilatin Human genes 0.000 description 1
- 101800001849 Urodilatin Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229920001586 anionic polysaccharide Polymers 0.000 description 1
- 150000004836 anionic polysaccharides Chemical class 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 101150000705 cas1 gene Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 238000002794 lymphocyte assay Methods 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical class OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 108010087904 neutravidin Proteins 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000009021 pre-vaccination Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000011701 zinc Chemical class 0.000 description 1
- 229910052725 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161506447P | 2011-07-11 | 2011-07-11 | |
| PCT/US2012/046222 WO2013009849A1 (en) | 2011-07-11 | 2012-07-11 | Parenteral norovirus vaccine formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201490258A1 EA201490258A1 (ru) | 2014-05-30 |
| EA029470B1 true EA029470B1 (ru) | 2018-03-30 |
Family
ID=47506489
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201490258A EA029470B1 (ru) | 2011-07-11 | 2012-07-11 | Способ стимулирования формирования защитного иммунитета против норовируса |
| EA201792407A EA035442B1 (ru) | 2011-07-11 | 2012-07-11 | Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения |
| EA202090699A EA202090699A3 (ru) | 2011-07-11 | 2012-07-11 | Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201792407A EA035442B1 (ru) | 2011-07-11 | 2012-07-11 | Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения |
| EA202090699A EA202090699A3 (ru) | 2011-07-11 | 2012-07-11 | Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US9801934B2 (enExample) |
| EP (3) | EP4112074A1 (enExample) |
| JP (2) | JP6208659B2 (enExample) |
| KR (1) | KR102096937B1 (enExample) |
| CN (3) | CN105031637A (enExample) |
| AU (2) | AU2012282658B2 (enExample) |
| BR (1) | BR112014000656A2 (enExample) |
| CA (1) | CA2841356C (enExample) |
| CL (1) | CL2014000082A1 (enExample) |
| CR (2) | CR20190540A (enExample) |
| DK (1) | DK3299030T3 (enExample) |
| DO (2) | DOP2014000004A (enExample) |
| EA (3) | EA029470B1 (enExample) |
| EC (1) | ECSP14013201A (enExample) |
| ES (2) | ES2926487T3 (enExample) |
| GE (1) | GEP201706668B (enExample) |
| HK (2) | HK1199202A1 (enExample) |
| IL (1) | IL230356B (enExample) |
| MA (1) | MA35414B1 (enExample) |
| MX (2) | MX356586B (enExample) |
| MY (1) | MY170746A (enExample) |
| PE (1) | PE20140845A1 (enExample) |
| PH (3) | PH12021551773A1 (enExample) |
| PL (2) | PL3299030T3 (enExample) |
| SG (1) | SG10201605644WA (enExample) |
| TN (1) | TN2014000008A1 (enExample) |
| UA (1) | UA117732C2 (enExample) |
| WO (1) | WO2013009849A1 (enExample) |
| ZA (2) | ZA201401012B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE032422T2 (en) | 2006-09-29 | 2017-09-28 | Takeda Vaccines Inc | Norovirus vaccine preparations |
| US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
| SG10201601660YA (en) | 2007-09-18 | 2016-04-28 | Takeda Vaccines Inc | Method of conferring a protective immune response to norovirus |
| EA029470B1 (ru) | 2011-07-11 | 2018-03-30 | Такеда Вэксинс, Инк. | Способ стимулирования формирования защитного иммунитета против норовируса |
| SG10202107054TA (en) | 2013-10-03 | 2021-08-30 | Takeda Vaccines Inc | Methods of detection and removal of rhabdoviruses from cell lines |
| US20160310412A1 (en) | 2013-12-16 | 2016-10-27 | Takeda Pharmaceutical Company Limited | Microneedle |
| CN107184970A (zh) * | 2017-02-16 | 2017-09-22 | 北京生物制品研究所有限责任公司 | 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途 |
| GB201703644D0 (en) | 2017-03-07 | 2017-04-19 | Elopak As | Improvements in or relating to toller mounting arrangements |
| CA3061678A1 (en) * | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| WO2019158653A1 (en) * | 2018-02-15 | 2019-08-22 | Icon Genetics Gmbh | Immunogenic composition and vaccine for generating an immune response to norovirus |
| US20210121511A1 (en) * | 2018-05-29 | 2021-04-29 | Unm Rainforest Innovations | Virus-like particle compositions and methods of using same |
| CN109265542B (zh) * | 2018-09-27 | 2021-06-15 | 国药中生生物技术研究院有限公司 | 特异性结合诺如病毒gii.4基因型vp1蛋白或vlp的抗体及其制备方法和应用 |
| AR117462A1 (es) * | 2018-12-20 | 2021-08-04 | Takeda Vaccines Inc | Vacuna contra norovirus, formulaciones y métodos |
| EP4087604A4 (en) * | 2020-01-08 | 2023-11-01 | Bharat Biotech International Limited | COMPOSITIONS OF VIRAL VACCINES AND THEIR PREPARATION METHODS |
| US20240156942A1 (en) | 2021-03-29 | 2024-05-16 | Denka Company Limited | Peptide of Norovirus Origin, Polynucleotide, Antibody, Composition, Method for Identifying Neutralizing Epitope for Norovirus |
| US20240238401A1 (en) | 2021-05-21 | 2024-07-18 | Takeda Vaccines, Inc. | Solid composition, freeze-drying method and glass vial |
| CN118252924A (zh) * | 2022-12-27 | 2024-06-28 | 远大赛威信生命科学(南京)有限公司 | 用于诱发哺乳动物针对诺如病毒的免疫反应的药物组合物及其制备方法和用途 |
| WO2025077799A1 (en) * | 2023-10-12 | 2025-04-17 | Chengdu Kanghua Biological Products Co., Ltd. | Method of preparing norovirus vaccine without adjuvant |
| WO2025076792A1 (en) * | 2023-10-12 | 2025-04-17 | Chengdu Kanghua Biological Product Co., Ltd. | Methods of preparing norovirus vaccine with low amounts of adjuvant |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010017542A1 (en) * | 2008-08-08 | 2010-02-11 | Ligocyte Pharmaceuticals, Inc. | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
| US20100266636A1 (en) * | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6572862B1 (en) | 1989-11-08 | 2003-06-03 | Baylor College Of Medicine | Methods and reagents to detect and characterize Norwalk and related viruses |
| AU1893592A (en) | 1991-03-25 | 1992-10-21 | Board Of Trustees Of The Leland Stanford Junior University | Norwalk virus human gastroenteritis agent and molecular cloning of corresponding cdnas |
| JPH07509122A (ja) | 1992-04-08 | 1995-10-12 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，アズ レプリゼンテッド バイ ザ セクレター，デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 野生型麻疹ウイルス糖タンパク質：ワクチンおよびその検出方法 |
| AU4851493A (en) | 1992-09-07 | 1994-03-29 | Baylor College Of Medicine | Methods and reagents to detect and characterize norwalk and related viruses |
| EP0689454B2 (en) | 1993-03-23 | 2005-02-23 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |
| US5788970A (en) | 1994-03-29 | 1998-08-04 | The University Of Maryland College Park | Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon |
| BR9507657A (pt) | 1994-05-16 | 1997-09-09 | Merck & Co Inc | Proteina isolada e purificada de papilomavirus recombinante capsideos particulas semelhantes a virus processos a virus processos para produzir a proteina para tratar ou prevenir a infecçao por papilomavirus para produzir uma proteina de capsideo de papilomavirus recombinante montada em um capsideo ou particula semelhante a virus e para induzir uma resposta imune em um animal vertebrado composiçoes farmacêuticas kit para a detecçao de papilomavirus ou anticorpos para papilomavirus e sistema sinte |
| US5645051A (en) | 1995-04-21 | 1997-07-08 | Dura Pharmaceuticals, Inc. | Unit dose dry powder inhaler |
| US5861241A (en) | 1995-08-16 | 1999-01-19 | University Of Massachusetts | Monoclonal antibodies for detecting Norwalk virus |
| GB9525083D0 (en) | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
| US5834015A (en) * | 1996-09-11 | 1998-11-10 | Albany Medical College | Protein-lipid vesicles and autogenous vaccine comprising the same |
| US5953727A (en) | 1996-10-10 | 1999-09-14 | Incyte Pharmaceuticals, Inc. | Project-based full-length biomolecular sequence database |
| US6491919B2 (en) | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
| SK138199A3 (en) | 1997-04-08 | 2000-06-12 | Merck & Co Inc | Human papillomavirus antigen formulation and method for stabilizing a population of virus-like purified particles, derived from protein l1 or protein l1 and l2 of human papillomavirus |
| CA2288129A1 (en) | 1997-05-01 | 1998-11-12 | Chiron Corporation | Use of virus-like particles as adjuvants |
| US20040265377A1 (en) | 1997-10-27 | 2004-12-30 | Harry Seager | Solid dispersing vaccine composition for oral delivery |
| BR9913026A (pt) | 1998-08-14 | 2001-09-25 | Merck & Co Inc | Processo de purificação de partìculas semelhantes a vìrus (vlps) de papilomavìrus recombinante, e, processo de preparação de um produto de vlp de papilomavìrus humano purificado adequado para uso em uma vacina para humano |
| CA2354444A1 (en) | 1998-12-17 | 2000-06-22 | Merck & Co., Inc. | Synthetic virus-like particles with heterologous epitopes |
| SI1150712T1 (sl) | 1999-02-05 | 2009-02-28 | Merck & Co Inc | Pripravek cepiva proti humanem papiloma virusu |
| KR100771402B1 (ko) | 1999-06-22 | 2007-10-30 | 국립감염증연구소장이 대표하는 일본국 | Ｓｒｓｖ 검출 킷트 |
| JP2002020399A (ja) | 2000-07-10 | 2002-01-23 | Osaka Prefecture | ノルウォークウイルス（ｎｖ）を認識するモノクローナル抗体 |
| GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| WO2003068933A2 (en) | 2002-02-14 | 2003-08-21 | Novavax, Inc. | Optimization of gene sequences of virus-like particles for expression in insect cells |
| GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| GB0206359D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| EP1494651A4 (en) | 2002-04-11 | 2010-10-13 | Medimmune Vaccines Inc | PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM |
| GB0302218D0 (en) | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
| EP1545625B1 (en) | 2002-06-07 | 2011-08-24 | Kentucky Bioprocessing, LLC | Flexible vaccine assembly and vaccine delivery platform |
| PL375306A1 (en) | 2002-06-20 | 2005-11-28 | Cytos Biotechnology Ag | Packaged virus-like particles for use as adjuvants: method of preparation and use |
| JP4675317B2 (ja) | 2003-01-30 | 2011-04-20 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | アジュバント化インフルエンザワクチン |
| US20040213745A1 (en) | 2003-02-20 | 2004-10-28 | Vincent Sullivan | Powder formulations of rSEB for improved vaccination |
| US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| WO2005032457A2 (en) | 2003-07-21 | 2005-04-14 | Boyce Thompson Institute For Plant Research, Inc. | Vectors and methods for immunization against norwalk virus using transgenic plants |
| WO2005030806A2 (en) | 2003-09-24 | 2005-04-07 | Montana State University | Norovirus monoclonal antibodies and peptides |
| US7795242B2 (en) | 2003-10-15 | 2010-09-14 | The Brigham And Women's Hospital, Inc. | Methods and compositions for immunomodulation |
| US20050215501A1 (en) | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
| FR2863890B1 (fr) | 2003-12-19 | 2006-03-24 | Aventis Pasteur | Composition immunostimulante |
| US7481997B1 (en) | 2004-02-12 | 2009-01-27 | Montana State University | Snow mountain virus genome sequence, virus-like particles and methods of use |
| US20050260225A1 (en) | 2004-05-18 | 2005-11-24 | Goldberg Joanna B | Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens |
| CU23496A1 (es) | 2004-09-03 | 2010-02-23 | Ct Ingenieria Genetica Biotech | Composición vacunal contra el virus de la hepatitis c |
| JP4993301B2 (ja) | 2004-10-20 | 2012-08-08 | サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー | 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン |
| GB0428394D0 (en) | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
| RU2007129840A (ru) | 2005-01-05 | 2009-02-20 | Филадельфия Хелт Энд Эдьюкейшн Корпорейшн Д/Б/А Дрексел Юниверсити Колледж Оф Медисин (Us) | Средства доставки, биологически активные вещества и вирусные вакцины |
| US8168771B2 (en) | 2005-01-31 | 2012-05-01 | The Johns Hopkins University | Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants |
| NZ580974A (en) | 2005-02-18 | 2011-05-27 | Novartis Vaccines & Diagnostic | Immunogens from uropathogenic escherichia coli |
| US7767212B2 (en) | 2005-03-18 | 2010-08-03 | Cytos Biotechnology Ag | CAT allergen conjugates and uses thereof |
| KR20080018176A (ko) | 2005-06-01 | 2008-02-27 | 다우 글로벌 테크놀로지스 인크. | 다가 바이러스 유사 입자 생산 방법 |
| EP1736538A1 (en) | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
| JP5215865B2 (ja) | 2005-11-22 | 2013-06-19 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | ノロウイルス抗原およびサポウイルス抗原 |
| JP2007145775A (ja) | 2005-11-29 | 2007-06-14 | Falco Life Science:Kk | ノロウイルスｇｉの高感度検出方法 |
| US20080029915A1 (en) * | 2006-08-02 | 2008-02-07 | Courtoy Nv | Rotary tablet press |
| HUE032422T2 (en) * | 2006-09-29 | 2017-09-28 | Takeda Vaccines Inc | Norovirus vaccine preparations |
| CN101553252A (zh) | 2006-12-06 | 2009-10-07 | 诺华有限公司 | 包含来自于四株流感病毒的抗原的疫苗 |
| CA2683977C (en) * | 2007-03-14 | 2017-04-25 | Ligocyte Pharmaceuticals, Inc. | A method of norovirus virus-like particle purification comprising ion exchange chromatography |
| US8648229B2 (en) | 2007-09-12 | 2014-02-11 | Australian Centre For Plant Functional Genomics Pty Ltd | Plant seed active transcriptional control sequences |
| SG10201601660YA (en) | 2007-09-18 | 2016-04-28 | Takeda Vaccines Inc | Method of conferring a protective immune response to norovirus |
| EP2381959A1 (en) * | 2009-01-22 | 2011-11-02 | Pharmathene Inc. | Stable vaccine compositions and methods of use |
| WO2010092476A1 (en) * | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccine regimens for pandemic-associated strains |
| US20110070260A1 (en) | 2009-09-09 | 2011-03-24 | Baric Ralph S | Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use |
| SG182636A1 (en) | 2010-01-21 | 2012-08-30 | Ligocyte Pharmaceuticals Inc | Targeted heterologous antigen presentation on calicivirus virus-like particles |
| WO2011150258A1 (en) * | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Dose selection of adjuvanted synthetic nanocarriers |
| EA029470B1 (ru) | 2011-07-11 | 2018-03-30 | Такеда Вэксинс, Инк. | Способ стимулирования формирования защитного иммунитета против норовируса |
| JOP20130186B1 (ar) | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | تنقية الجزيئات الشبيهة بالفيروسات |
| EP3389695A4 (en) | 2015-12-16 | 2019-10-09 | The Walter and Eliza Hall Institute of Medical Research | INHIBITION OF CYTOKININDUCED SH2 PROTEIN IN NK CELLS |
| EP4338799A3 (en) | 2016-10-18 | 2024-06-05 | Regents of the University of Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
| CN112292390A (zh) | 2018-05-03 | 2021-01-29 | 得克萨斯大学体系董事会 | 经工程改造以在免疫检查点阻断的情况下表达嵌合抗原受体的自然杀伤细胞 |
| WO2020041192A1 (en) | 2018-08-20 | 2020-02-27 | Takeda Vaccines, Inc. | Vlp formulations |
| AR117462A1 (es) | 2018-12-20 | 2021-08-04 | Takeda Vaccines Inc | Vacuna contra norovirus, formulaciones y métodos |
| KR20210129105A (ko) | 2019-02-15 | 2021-10-27 | 에디타스 메디신, 인코포레이티드 | 면역치료법을 위한 변형된 자연 살해(nk) 세포 |
-
2012
- 2012-07-11 EA EA201490258A patent/EA029470B1/ru not_active IP Right Cessation
- 2012-07-11 GE GEAP201213384A patent/GEP201706668B/en unknown
- 2012-07-11 PH PH1/2021/551773A patent/PH12021551773A1/en unknown
- 2012-07-11 PE PE2014000054A patent/PE20140845A1/es active IP Right Grant
- 2012-07-11 BR BR112014000656A patent/BR112014000656A2/pt not_active Application Discontinuation
- 2012-07-11 EP EP22176978.9A patent/EP4112074A1/en active Pending
- 2012-07-11 MY MYPI2014000073A patent/MY170746A/en unknown
- 2012-07-11 EP EP17199372.8A patent/EP3299030B1/en active Active
- 2012-07-11 CA CA2841356A patent/CA2841356C/en active Active
- 2012-07-11 CN CN201510262891.2A patent/CN105031637A/zh active Pending
- 2012-07-11 PL PL17199372.8T patent/PL3299030T3/pl unknown
- 2012-07-11 DK DK17199372.8T patent/DK3299030T3/da active
- 2012-07-11 MX MX2014000411A patent/MX356586B/es active IP Right Grant
- 2012-07-11 KR KR1020147003571A patent/KR102096937B1/ko active Active
- 2012-07-11 MX MX2018006816A patent/MX379496B/es unknown
- 2012-07-11 CR CR20190540A patent/CR20190540A/es unknown
- 2012-07-11 ES ES17199372T patent/ES2926487T3/es active Active
- 2012-07-11 ES ES12811916.1T patent/ES2656527T3/es active Active
- 2012-07-11 PL PL12811916T patent/PL2731621T3/pl unknown
- 2012-07-11 PH PH1/2014/500093A patent/PH12014500093A1/en unknown
- 2012-07-11 AU AU2012282658A patent/AU2012282658B2/en active Active
- 2012-07-11 HK HK14112697.5A patent/HK1199202A1/xx unknown
- 2012-07-11 EA EA201792407A patent/EA035442B1/ru not_active IP Right Cessation
- 2012-07-11 CN CN201810373895.1A patent/CN108567975A/zh active Pending
- 2012-07-11 WO PCT/US2012/046222 patent/WO2013009849A1/en not_active Ceased
- 2012-07-11 JP JP2014520273A patent/JP6208659B2/ja active Active
- 2012-07-11 EP EP12811916.1A patent/EP2731621B1/en active Active
- 2012-07-11 SG SG10201605644WA patent/SG10201605644WA/en unknown
- 2012-07-11 EA EA202090699A patent/EA202090699A3/ru unknown
- 2012-07-11 CN CN201280043691.2A patent/CN103874507A/zh active Pending
- 2012-11-07 UA UAA201401321A patent/UA117732C2/uk unknown
-
2013
- 2013-03-15 US US13/840,403 patent/US9801934B2/en active Active
-
2014
- 2014-01-07 IL IL230356A patent/IL230356B/en active IP Right Grant
- 2014-01-07 TN TNP2014000008A patent/TN2014000008A1/en unknown
- 2014-01-10 DO DO2014000004A patent/DOP2014000004A/es unknown
- 2014-01-10 CL CL2014000082A patent/CL2014000082A1/es unknown
- 2014-02-06 MA MA36741A patent/MA35414B1/fr unknown
- 2014-02-10 ZA ZA2014/01012A patent/ZA201401012B/en unknown
- 2014-02-11 CR CR20140069A patent/CR20140069A/es unknown
- 2014-02-11 EC ECSP14013201 patent/ECSP14013201A/es unknown
- 2014-12-18 HK HK16102061.2A patent/HK1215154A1/zh unknown
-
2015
- 2015-02-09 ZA ZA2015/00915A patent/ZA201500915B/en unknown
- 2015-02-19 AU AU2015200836A patent/AU2015200836B2/en active Active
- 2015-07-10 US US14/796,614 patent/US9867876B2/en active Active
-
2017
- 2017-05-02 JP JP2017091755A patent/JP6613259B2/ja active Active
- 2017-12-08 US US15/836,030 patent/US10675341B2/en active Active
-
2018
- 2018-07-06 PH PH12018501515A patent/PH12018501515B1/en unknown
-
2020
- 2020-06-05 US US16/894,291 patent/US11701420B2/en active Active
-
2022
- 2022-02-04 DO DO2022000030A patent/DOP2022000030A/es unknown
-
2023
- 2023-05-24 US US18/322,679 patent/US20230338503A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100266636A1 (en) * | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
| WO2010017542A1 (en) * | 2008-08-08 | 2010-02-11 | Ligocyte Pharmaceuticals, Inc. | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA029470B1 (ru) | Способ стимулирования формирования защитного иммунитета против норовируса | |
| CN110869047B (zh) | 塞内卡病毒a免疫原性组合物及其方法 | |
| CA2526128A1 (en) | Severe acute respiratory syndrome dna vaccine compositions and methods of use | |
| KR102075393B1 (ko) | 중증 열성 혈소판 감소 증후군(sfts) 바이러스 감염 질환 예방 또는 치료용 백신 조성물 | |
| TWI656213B (zh) | 豬小病毒５ａ、用法及疫苗 | |
| WO2021188818A1 (en) | Vaccine constructs and compositions and methods of use thereof | |
| EP3116540B1 (en) | Compositions and methods for treating, including preventing, parvovirus infections and related diseases | |
| HK40085324A (en) | Parenteral norovirus vaccine formulations | |
| WO2025189435A1 (zh) | 针对猫fipv的多表位抗原构建rna疫苗的方法 | |
| CN118846031A (zh) | 一种四价重组手足口病疫苗及其制备方法 | |
| EA041112B1 (ru) | Иммуногенные композиции senecavirus a и способы с ними | |
| HK1198136B (en) | Parenteral norovirus vaccine formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |